Prima Biomed and Dendreon cannot and should not be positioned...

Prima Biomed and Dendreon cannot and should not be positioned along side each other
For too long mow posters here have put them in the same basket
This came about at the start of the year when Dendreon and its prostate care drug Provenge after gaining FDA approval hit the high spots as investors piled in and sent the SP soaring 80 percent to over US$50 in a short space of time
And of course we all saw a golden lining for Cvac thinking and believing that once approved,if approved,it would follow and similar path.
Now Dendreon has lost all it's glitter and is now trading around US$8 the level it was at before it took off

However one has to consider why Dendreon has fallen off the perch, and there are many reasons which have been mentioned in several reports
To me one of the overiding issues apart from the cost of a course of treatment for Provenge which has been reported as US$93000 was that other drugs for prostate cancer treatment have come on to the scene

Zyliga manufactured by Johnson % Johnson recently gained approval and is reported to be far better for patients than Provenge because it relieves symptoms much faster.
More importantly it is administered in pill form whereas patients given Provenge have white blood cells taken, have them combined with vaccine components and then given back to the patient by infusion

Now we come to Prima biomed and its Cvac
As far as I can remember the management have said that at present they have no competitor, therein lies the big difference betwen Dendreon and Prima Biomed

Also our management team have closely watched the Dendreon story and no doubt many lessons are being learnt

The next two years will give them breathing space to overcome the problems Dendreon encountered

Keep the faith